Medigene AG
MediGene AG english
MediGene’s Etomoxir project delayed
Ad-hoc-announcement processed and transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MediGene’s Etomoxir project delayed
Martinsried – San Diego, April 19, 2002. Today, the German-American
biopharmaceutical company MediGene (Neuer Markt: MDG) announced a delay for one
of its seven drug development projects. The company has prematurely terminated
the phase 2 clinical trial for the therapeutic drug candidate Etomoxir for the
treatment of congestive heart failure and is now preparing for the development
of a lower dosage. During the clinical trial side effects occurred in a small
number of patients, which seem to be associated with treatment. In addition
recent preclinical results indicate that Etomoxir may be efficacious at a lower
dosage than that administered so far.
Therefore, significantly lower dosages should be tested during further
development. Administration of a lower dosage might improve the tolerability
for the patient and reduce the production costs of the drug candidate.
It is expected that due to additional clinical trials the total development
period for Etomoxir will be prolonged by approximately one year. The further
development will be financed within the current business plan. According to the
current business plan, the delay in MediGene’s Etomoxir project will have no
implications on the planned break-even point of MediGene.
For further information please contact:
MediGene AG email: investor@medigene.com
fax: ++49-89-85 65 29-20
Julia Hofmann, Public Relations phone: ++49-89-85 65 33-24
Michael Nettersheim, Investor Relations phone: ++49-89 85 65 29-46
end of ad-hoc-announcement (c)DGAP 19.04.2002
——————————————————————————–
WKN: 502090; ISIN: DE0005020903; Index: NEMAX-50
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
190759 Apr 02
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden